12/3
06:10 pm
biib
Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI® (lecanemab-irmb) Maintenance Treatment in Early Alzheimer's Disease at the Clinical Trials on Alzheimer's Disease (CTAD) Conference 2025
Low
Report
Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI® (lecanemab-irmb) Maintenance Treatment in Early Alzheimer's Disease at the Clinical Trials on Alzheimer's Disease (CTAD) Conference 2025
12/2
04:40 pm
biib
New Data Presented at the Clinical Trials on Alzheimer's Disease (CTAD) Conference 2025 Confirms Pharmacological Effect of LEQEMBI® (lecanemab-irmb) on Neurotoxic Aß Protofibrils in CSF
Low
Report
New Data Presented at the Clinical Trials on Alzheimer's Disease (CTAD) Conference 2025 Confirms Pharmacological Effect of LEQEMBI® (lecanemab-irmb) on Neurotoxic Aß Protofibrils in CSF
12/1
07:48 am
biib
Stoke Therapeutics and Biogen Announce Presentations at the 2025 American Epilepsy Society Annual Meeting [Yahoo! Finance]
Low
Report
Stoke Therapeutics and Biogen Announce Presentations at the 2025 American Epilepsy Society Annual Meeting [Yahoo! Finance]
11/28
09:18 am
biib
Biogen (NASDAQ:BIIB) had its price target raised by analysts at Jefferies Financial Group Inc. from $190.00 to $210.00. They now have a "buy" rating on the stock.
Low
Report
Biogen (NASDAQ:BIIB) had its price target raised by analysts at Jefferies Financial Group Inc. from $190.00 to $210.00. They now have a "buy" rating on the stock.
11/25
07:30 am
biib
Eisai Completes Rolling Submission to U.S. FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status
Low
Report
Eisai Completes Rolling Submission to U.S. FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status
11/24
07:30 am
biib
Biogen and Dayra Therapeutics Announce Research Collaboration to Discover and Develop Oral Macrocyclic Peptides for a Range of Immunological Conditions
Medium
Report
Biogen and Dayra Therapeutics Announce Research Collaboration to Discover and Develop Oral Macrocyclic Peptides for a Range of Immunological Conditions
11/21
08:11 am
biib
Biogen (NASDAQ:BIIB) had its "neutral" rating reaffirmed by analysts at Piper Sandler.
Medium
Report
Biogen (NASDAQ:BIIB) had its "neutral" rating reaffirmed by analysts at Piper Sandler.
11/20
07:30 am
biib
Biogen to Highlight New Lecanemab Data and Scientific Advances at the 18th Clinical Trials on Alzheimer’s Disease Conference
Low
Report
Biogen to Highlight New Lecanemab Data and Scientific Advances at the 18th Clinical Trials on Alzheimer’s Disease Conference
11/19
07:04 pm
biib
Friedreich's Ataxia Market Research and Forecast Report 2025-2035: Gene Therapy and Small-Molecule Innovations Redefine Treatment Paradigms [Yahoo! Finance]
Medium
Report
Friedreich's Ataxia Market Research and Forecast Report 2025-2035: Gene Therapy and Small-Molecule Innovations Redefine Treatment Paradigms [Yahoo! Finance]
11/17
07:42 am
biib
Stoke Therapeutics and Biogen Announce Publication of Two-Year Natural History Data Demonstrating the Severity of Dravet Syndrome, Including Frequent Seizures and Significant Cognitive and Behavioral Impairments [Yahoo! Finance]
Low
Report
Stoke Therapeutics and Biogen Announce Publication of Two-Year Natural History Data Demonstrating the Severity of Dravet Syndrome, Including Frequent Seizures and Significant Cognitive and Behavioral Impairments [Yahoo! Finance]
11/17
07:30 am
biib
Biogen and Stoke Therapeutics Announce Publication of Two-Year Natural History Data Demonstrating the Severity of Dravet Syndrome, Including Frequent Seizures and Significant Cognitive and Behavioral Impairments
Low
Report
Biogen and Stoke Therapeutics Announce Publication of Two-Year Natural History Data Demonstrating the Severity of Dravet Syndrome, Including Frequent Seizures and Significant Cognitive and Behavioral Impairments
11/17
07:03 am
biib
High Dose Regimen of Nusinersen Receives Positive CHMP Opinion for the Treatment of Spinal Muscular Atrophy [Yahoo! Finance]
Low
Report
High Dose Regimen of Nusinersen Receives Positive CHMP Opinion for the Treatment of Spinal Muscular Atrophy [Yahoo! Finance]
11/17
06:00 am
biib
High Dose Regimen of Nusinersen Receives Positive CHMP Opinion for the Treatment of Spinal Muscular Atrophy
Low
Report
High Dose Regimen of Nusinersen Receives Positive CHMP Opinion for the Treatment of Spinal Muscular Atrophy
11/14
04:05 pm
biib
Biogen Completes Acquisition of Alcyone Therapeutics
Low
Report
Biogen Completes Acquisition of Alcyone Therapeutics
11/14
01:11 pm
biib
Biogen (NASDAQ:BIIB) had its "sell (d+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Biogen (NASDAQ:BIIB) had its "sell (d+)" rating reaffirmed by analysts at
Weiss Ratings.
11/13
06:40 pm
biib
“LEQEMBI®” (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease Approved in the United Kingdom [Yahoo! Finance]
Low
Report
“LEQEMBI®” (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease Approved in the United Kingdom [Yahoo! Finance]
11/9
01:13 am
biib
Low
Report
11/9
01:10 am
biib
Biogen (NASDAQ:BIIB) was downgraded by analysts at
Weiss Ratings from a "hold (c-)" rating to a "sell (d+)" rating.
Low
Report
Biogen (NASDAQ:BIIB) was downgraded by analysts at
Weiss Ratings from a "hold (c-)" rating to a "sell (d+)" rating.
11/6
08:10 am
biib
Biogen (NASDAQ:BIIB) was upgraded by analysts at Stifel Nicolaus from a "hold" rating to a "buy" rating. They now have a $202.00 price target on the stock, up previously from $144.00.
Low
Report
Biogen (NASDAQ:BIIB) was upgraded by analysts at Stifel Nicolaus from a "hold" rating to a "buy" rating. They now have a $202.00 price target on the stock, up previously from $144.00.
11/4
09:19 am
biib
Biogen (NASDAQ:BIIB) had its price target raised by analysts at Mizuho from $169.00 to $177.00. They now have an "outperform" rating on the stock.
Low
Report
Biogen (NASDAQ:BIIB) had its price target raised by analysts at Mizuho from $169.00 to $177.00. They now have an "outperform" rating on the stock.
11/3
10:59 am
biib
Biogen (NASDAQ:BIIB) was given a new $157.00 price target on by analysts at Tudor Pickering.
Low
Report
Biogen (NASDAQ:BIIB) was given a new $157.00 price target on by analysts at Tudor Pickering.
11/3
08:03 am
biib
Biogen (NASDAQ:BIIB) had its price target raised by analysts at Sanford C. Bernstein from $155.00 to $157.00. They now have a "market perform" rating on the stock.
Low
Report
Biogen (NASDAQ:BIIB) had its price target raised by analysts at Sanford C. Bernstein from $155.00 to $157.00. They now have a "market perform" rating on the stock.
11/3
07:30 am
biib
Biogen to Highlight Scientific Progress in Rare Kidney Disease at American Society of Nephrology (ASN) Kidney Week 2025
Low
Report
Biogen to Highlight Scientific Progress in Rare Kidney Disease at American Society of Nephrology (ASN) Kidney Week 2025
11/1
09:17 am
biib
Biogen (NASDAQ:BIIB) had its price target raised by analysts at Wells Fargo & Company from $140.00 to $155.00.
Low
Report
Biogen (NASDAQ:BIIB) had its price target raised by analysts at Wells Fargo & Company from $140.00 to $155.00.
11/1
09:17 am
biib
Biogen (NASDAQ:BIIB) had its price target raised by analysts at Wedbush from $135.00 to $143.00. They now have a "neutral" rating on the stock.
Low
Report
Biogen (NASDAQ:BIIB) had its price target raised by analysts at Wedbush from $135.00 to $143.00. They now have a "neutral" rating on the stock.